米非司酮配伍米索前列醇联合清宫术终止瘢痕子宫妊娠的疗效和安全性

Curative Effect and Safety of Mifepristone and Misoprostol Combined with Uterine Curettage in the Termination of Scar Uterine Pregnancy

目的研究米非司酮配伍米索前列醇联合清宫术终止瘢痕子宫妊娠的疗效和安全性。方法选取我站2015年1月至2016年12月收治的自愿终止妊娠的106例瘢痕子宫妊娠患者,分为试验组与对照组各53例。试验组采用米非司酮配伍米索前列醇联合清宫术终止妊娠,对照组采用单纯清宫术终止妊娠。比较两组患者的临床治疗效果、宫颈扩张程度、阴道出血量、术后出血时间及不良反应发生情况。结果试验组的治疗总有效率为98.1%,显著高于对照组的84.9%(P<0.05)。试验组的宫颈扩张困难率为0.0%,显著低于对照组的62.3%(P<0.05)。试验组的阴道出血量和术后出血时间均明显优于对照组(P<0.05)。试验组的不良反应发生率为5.7%,显著低于对照组的54.7%(P<0.05)。结论米非司酮配伍米索前列醇联合清宫术能够提高临床治疗效果,减少阴道出血量和不良反应,提高终止妊娠安全性,值得临床推广。

Objective To study the curative effect and safety of mifepristone and misoprostol combined with uterine curettage in the termination of scar uterine pregnancy. Methods 106 cases of patients with voluntary termination of scar uterine pregnancy in our station from January 2015 to December 2016 were selected and divided into experimental group and control group, with 53 cases in each group. The experimental group reveived mifepristone and misoprostol combined with uterine curettage for termination, while the control group only received uterine curettage for termination. The clinical treatment effect, cervical dilation degree, vaginal bleeding volume, postoperative bleeding time and adverse reactions were compared between the two groups. Results The total effective rate of the experimental group was 98.1%, significantly higher than 84.9% of the control group （P 〈0.05）. The difficulty rate of cervical dilatation of the experimental group was 0.0%, significantly lower than 62.3% of the control group （P 〈0.05）. The vaginal bleeding volume and postoperative bleeding time of the experimental group was significantly better than that of the control group （P 〈0.05）. The incidence of adverse reactions of the experimental group was 5.7%, significantly lower than 54.7% of the control group （P 〈0.05）. Conclusions Mifepristone and misoprostol combined with uterine curettage can improve clinical treatment effect, reduce the vaginal bleeding volume and adverse reactions, and improve the safety of termination, which is worthy of clinical promotion.